Further analyses showed that tumoral HHLA2 levels and stromal expression of several QIF markers (including PD-L1, B7H3 and Galectin-9) were associated with tumor phenotype, microenvironmental immunity level and clinical outcomes. The gene discussed is CD276; the disease is neoplasm.